Nov 10 (Reuters) - Influential short-seller Citron
Research's Andrew Left, who accused Mallinckrodt (N:MNK) Plc MNK.N of
being an offender of the reimbursement system, told CNBC on
Tuesday that he has a short position on the company's stock.
Mallinckrodt's stock plunged 26 percent on Monday after
Left's tweet on the drugmaker. urn:newsml:reuters.com:*:nL3N1345LP
However, the stock recovered on Tuesday and gained 6 percent
by afternoon as Left did not lay out specific accusations
against the company.
Citron published a scathing report on Valeant
Pharmaceuticals International Inc VRX.TO VRX.N late October,
accusing the Canadian drugmaker of using specialty pharmacies to
inflate revenue. Shares plunged 40 percent on the day.
"My short on Valeant has been significantly scaled down from
where it was earlier," Left told CNBC on Tuesday.